FOLLOWUS
Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medcine,Shanghai,China
纸质出版日期:2013,
网络出版日期:2013-4-2,
Scan for full text
Tian, W., Chen, Sy. Recent advances in the molecular basis of anti-neoplastic mechanisms of oridonin., Chin. J. Integr. Med. 19, 315–320 (2013). https://doi.org/10.1007/s11655-013-1437-3
Wei Tian, Si-yu Chen. Recent advances in the molecular basis of anti-neoplastic mechanisms of oridonin[J]. Chinese Journal of Integrative Medicine, 2013,19(4):315-320.
Tian, W., Chen, Sy. Recent advances in the molecular basis of anti-neoplastic mechanisms of oridonin., Chin. J. Integr. Med. 19, 315–320 (2013). https://doi.org/10.1007/s11655-013-1437-3 DOI:
Wei Tian, Si-yu Chen. Recent advances in the molecular basis of anti-neoplastic mechanisms of oridonin[J]. Chinese Journal of Integrative Medicine, 2013,19(4):315-320. DOI: 10.1007/s11655-013-1437-3.
Oridonin
a diterpenoid isolated from Rabdosia rubescens
has been proven to possess various pharmacological and physiological effects such as anti-inflammation
anti-bacterial
and anti-neoplastic
although in recent years
more attention has been paid to its anti-neoplastic effects. For example
oridonin can trigger cell cycle arrest
apoptosis
and autophagy in different neoplastic cell lines. This review summarizes the considerable knowledge about the action mechanisms of oridonin that has been studied in recent years. The present observations reveal the novel anti-neoplastic effects of oridonin
suggesting that it may be effective as a potent alternative or adjunct drug to conventional chemotherapy.
Oridonin
a diterpenoid isolated from Rabdosia rubescens
has been proven to possess various pharmacological and physiological effects such as anti-inflammation
anti-bacterial
and anti-neoplastic
although in recent years
more attention has been paid to its anti-neoplastic effects. For example
oridonin can trigger cell cycle arrest
apoptosis
and autophagy in different neoplastic cell lines. This review summarizes the considerable knowledge about the action mechanisms of oridonin that has been studied in recent years. The present observations reveal the novel anti-neoplastic effects of oridonin
suggesting that it may be effective as a potent alternative or adjunct drug to conventional chemotherapy.
oridoninanti-neoplasmcell cycle arrestapoptosisautophagy
oridoninanti-neoplasmcell cycle arrestapoptosisautophagy
Fan QX, Li XY, Wang RL, Fan KS, Gao GQ, Chen HM, et al. Treatment with oridonin in 287 patients with esophageal and gastric cardia neoplasm. Chin J Surgery Integr Tradit (Chin) 1997;3:380–381.
Han QB, Li ML, Li SH, Mou YK, Lin ZW, Sun HD. Entkaurane diterpenoids from Isodon rubescens var. lushanensis. Chem Pharm Bull 2003;51:790–793.
Ikezoe T, Chen SS, Tong XJ, Heber D, Taquchi, Koeffler HP. Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol 2003;23:1187–1189.
Fujita E, Nagao Y, Node M, Kaneko K, Nakazawa S, Kuroda H. Antitumor activity of the isodon diterpenoids: structural requirements for the activity. Cell Mol Life Sci 1976;32:203–206.
Liu CJ, Zhao ZH. Research progress of oridonin. Chin Pharm J (Chin) 1998;33:577–581.
Ding L, Zhou Q, Wang L, Wang W, Zhang S, Liu B. Comparison of cytotoxicity and DNA damage potential induced by ent-kaurene diterpenoids from Isodon plant. Nat Prod Res 2009;15:1–10.
Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821–1828.
DiPietrantonio AM, Hsieh TC, Olson SC, Wu JM. Regulation of G1/S transition and induction of apoptosis in HL-60 leukemia cells by fenretinide (4HPR). Int J Cancer 1998;78:53–61.
Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007;8:275–283.
Gao FH, Hu XH, Li W, Liu H, Zhang YJ, Guo ZY, et al. Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer 2010;10:610.
Wang H, Ye Y, Chui JH, Zhu GY, Li YW, Fong DW, et al. Oridonin induces G2/M cell cycle arrest and apoptosis through MAPK and p53 signaling pathways in HepG2 cells. Oncol Rep 2010;24:647–651.
Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera S, Ikejima T. Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys 2009;490:70–75.
Cui Q, Yu JH, Wu JN, Tashiro S, Onodera S, Minami M, et al. P53-mediated cell cycle arrest and apoptosis through a caspase-3-independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells. Acta Pharmacol Sin 2007;28:1057–1066.
He XJ, Wang HJ, Xia YJ, Ye ZY, Tao HQ. Empirical study of oridonin-induced gastric cancer cells MKN45 apoptosis. Chin J Gastrointest Surg (Chin) 2009;12:607–610.
Kang N, Zhang JH, Qiu F, Chen S, Tashiro S, Onodera S, et al. Induction of G(2)/M phase arrest and apoptosis by oridonin in human laryngeal carcinoma cells. J Nat Prod 2010;73:1058–1063.
Zhu Y, Xie L, Chen G, Wang H, Zhang R. Effects of oridonin on proliferation of HT29 human colon carcinoma cell lines both in vitro and in vivo in mice. Pharmazie 2007;62:439–444.
Ren KK, Wang HZ, Xie LP, Chen DW, Liu X, Sun J, et al. The effects of oridonin on cell growth, cell cycle, cell migration and differentiation in melanoma cells. J Ethnopharmacol 2006;103:176–180.
Chen S, Gao J, Halicka HD, Huang X, Traganos F, Darzynkiewicz Z. The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage. Int J Oncol 2005;26:579–588.
Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL, Wu JM. Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun 2005;337:224–231.
Meier P, Finch A, Evan G. Apoptosis in development. Nature 2000;407:796–801.
Cai J, Yang J, Jones DP. Mitochondrial control of apoptosis: the role of cytochrome c. Biochim Biophys Acta 1998;1366:139–149.
Wilson MR. Apoptotic signal transduction: emerging pathways. Biochem Cell Biol 1998;76:573–582.
Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with BAX. Nature 1994;369:321.
Kang N, Zhang JH, Qiu F, Tashiro S, Onodera S, Ikejima T. Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways. Cancer Lett 2010;294:147–158.
Chen JH, Wang SB, Li EM, Chen LM, Yuan SJ, Wang RL, et al. Inhibitory effect of Oridonin injection on heterotransplanted gastric adenocarcinoma in nude mice and its mechanism. Chin J Oncol (Chin) 2008;30:89–92.
Li D, Wu LJ, Tashiro S, Onodera S, Ikejima T. Oridonin induces human epidermoid carcinoma A431 cell apoptosis through tyrosine kinase and mitochondrial pathway. J Asian Nat Prod Res 2008;10:77–87.
Liu J, Huang R, Lin D, Wu X, Peng J, Lin Q, et al. Apoptotic effect of oridonin on NB4 cells and its mechanism. Leuk Lymphoma 2005;46:593–597.
Liu JJ, Huang RW, Lin DJ, Wu XY, Peng J, Pan XL, et al. Antiproliferation effects of oridonin on HPB-ALL cells and its mechanisms of action. Am J Hematol 2006;81:86–94.
Liu JJ, Huang RW, Lin DJ, Wu XY, Peng J, Pan XL, et al. Oridonin-induced apoptosis in leukemia K562 cells and its mechanism. Neoplasma 2005;52:225–230.
Zhang JF, Liu JJ, Liu PQ, Lin DJ, Li XD, Chen GH. Oridonin inhibits cell growth by induction of apoptosis on human hepatocelluar carcinoma BEL-7402 cells. Hepatol Res 2006;35:104–110.
Liu YQ, You S, Tashiro S, Onodera S, Ikejima T. Oridonin induced U937 cell apoptosis through ERK pathway. China J Chin Mater Med (Chin) 2005;30:1856–1859.
Ikezoe T, Yang Y, Bandobashi K, Saito T, Takemoto S, Machida H, et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther 2005;4:578–586.
Jin S, Shen JN, Wang J, Huang G, Zhou JG. Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells. Cancer Biol Ther 2007;6:261–268.
Zhang Y, Wu Y, Wu D, Tashiro S, Onodera S, Ikejima T. NF-kappa B facilitates oridonin-induced apoptosis and autophagy in HT1080 cells through a p53-mediated pathway. Arch Biochem Biophys 2009;489:25–33.
Hu HZ, Yang YB, Xu XD, Shen HW, Shu YM, Ren Z, et al. Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta Pharmacol Sin 2007;28:1819–1826.
Wang H, Ye Y, Pan SY, Zhu GY, Li YW, Fong DW, et al. Proteomic identification of proteins involved in the anticancer activities of oridonin in HepG2 cells. Phytomedicine 2011;18:163–169.
Zhang JF, Chen GH, Lu MQ, Li H, Cai CJ, Yang Y. Change of Bcl-2 expression and telomerase during apoptosis induced by oridonin on human hepatocelluar carcinoma cells. China J Chin Mater Med (Chin) 2006;31:1811–1814.
Liu JJ, Wu XY, Peng J, Pan XL, Lu HL. Antiproliferation effects of oridonin on HL-60 cells. Ann Hematol 2004;83:691–695.
Ye LH, Chen YL, Tao SX, Jiang XQ, Li WJ, Qian WL, et al. Autophagy of prostate cancer PC-3 cells under the induction of oridonin. Natl Med J China (Chin) 2010;90:2984–2988.
Cui Q, Tashiro S, Onodera S, Minami M, Ikejima T. Oridonin induced autophagy in human cervical carcinoma HeLa cells through Ras, JNK, and P38 regulation. J Pharmacol Sci 2007;105:317–325.
Zhang Y, Wu Y, Tashiro S, Onodera S, Ikejima T. Involvement of PKC signal pathways in oridonin-induced autophagy in HeLa cells: a protective mechanism against apoptosis. Biochem Biophys Res Commun 2009;378:273–278.
Cui Q, Tashiro S, Onodera S, Ikejima T. Augmentation of oridonin-induced apoptosis observed with reduced autophagy. J Pharmacol Sci 2006;101:230–239.
Gao F, Tang Q, Yang P, Fang Y, Li W, Wu Y. Apoptosis inducing and differentiation enhancement effect of oridonin on the all-trans-retinoic acid-sensitive and -resistant acute promyelocytic leukemia cells. Int J Lab Hematol 2010;32:e114–122.
Cheng Y, Qiu F, Ye YC, Guo ZM, Tashiro S, Onodera S, et al. Autophagy inhibits reactive oxygen species-mediated apoptosis via activating p38-nuclear factor-kappa B survival pathways in oridonin-treated murine fibrosarcoma L929 cells. FEBS J 2009;276:1291–1306.
Huang J, Wu L, Tashiro S, Onodera S, Ikejima T. Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, and mitochondrial signaling pathways. J Pharmacol Sci 2008;107:370–379.
Zhang YH, Wu YL, Tashiro SI, Onodera S, Ikejima T. Reactive oxygen species contribute to oridonin-induced apoptosis and autophagy in human cervical carcinoma HeLa cells. Acta Pharmacol Sin 2011;32:1266–1275.
Jiang J, Maeda A, Ji J, Baty CJ, Watkins SC, Greenberger JS, et al. Are mitochondrial reactive oxygen species required for autophagy? Biochem Biophys Res Commun 2011;412:55–60.
Wang H, Yu HS, Xue HW. Radiosensitization effect of oridonin on HepG2 in vitro. Med J Qilu (Chin) 2007;22:339–342.
Jin H, Tan X, Liu X, Ding Y. Down-regulation of AP-1 gene expression is an initial event in the oridonin-mediated inhibition of colorectal cancer: studies in vitro and in vivo. J Gastroenterol Hepatol 2011;26:706–715.
Jilani K, Qadri SM, Zelenak C, Lang F. Stimulation of suicidal erythrocyte death by oridonin. Arch Biochem Biophys 2011;511:14–20.
Liu J, Yang F, Zhang Y, Li J. Studies on the cellimmunosuppressive mechanism of Oridonin from Isodon serra. Int Immunopharmacol 2007;7:945–954.
0
浏览量
778
Downloads
28
CSCD
关联资源
相关文章
相关作者
相关机构